Amalgamated Bank Acquires New Stake in Tempus AI, Inc. $TEM

Amalgamated Bank bought a new position in Tempus AI, Inc. (NASDAQ:TEM) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 6,195 shares of the company’s stock, valued at approximately $394,000.

Several other institutional investors and hedge funds have also made changes to their positions in TEM. Concord Wealth Partners grew its holdings in shares of Tempus AI by 308.0% in the second quarter. Concord Wealth Partners now owns 408 shares of the company’s stock worth $26,000 after purchasing an additional 308 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new stake in Tempus AI during the 1st quarter valued at about $33,000. Nemes Rush Group LLC purchased a new stake in Tempus AI in the 1st quarter valued at about $39,000. Quarry LP bought a new position in Tempus AI in the 1st quarter worth about $44,000. Finally, Signaturefd LLC bought a new position in Tempus AI in the 1st quarter worth about $48,000. 24.22% of the stock is currently owned by institutional investors.

Insider Activity at Tempus AI

In related news, CEO Eric P. Lefkofsky sold 332,500 shares of the firm’s stock in a transaction on Thursday, September 25th. The shares were sold at an average price of $76.56, for a total transaction of $25,456,200.00. Following the completion of the transaction, the chief executive officer owned 9,141,032 shares of the company’s stock, valued at $699,837,409.92. This trade represents a 3.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Theodore Leonsis sold 44,000 shares of the business’s stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $69.90, for a total value of $3,075,600.00. Following the completion of the transaction, the director directly owned 86,756 shares of the company’s stock, valued at approximately $6,064,244.40. This trade represents a 33.65% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 1,105,282 shares of company stock worth $87,726,381 in the last ninety days. 26.27% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have recently weighed in on TEM. Canaccord Genuity Group decreased their price target on shares of Tempus AI from $110.00 to $95.00 and set a “buy” rating for the company in a research note on Wednesday. Guggenheim raised their price objective on Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, September 26th. Cowen cut Tempus AI from a “buy” rating to a “hold” rating in a report on Tuesday, October 21st. HC Wainwright dropped their price target on Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a research report on Friday. Finally, BTIG Research restated a “buy” rating and set a $96.00 price target on shares of Tempus AI in a research note on Wednesday. Seven research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $79.85.

Tempus AI Stock Performance

Shares of TEM opened at $71.56 on Friday. The company has a current ratio of 3.28, a quick ratio of 1.43 and a debt-to-equity ratio of 2.45. The firm has a market cap of $12.43 billion, a PE ratio of -60.13 and a beta of 4.86. Tempus AI, Inc. has a 12 month low of $31.36 and a 12 month high of $104.32. The stock has a fifty day moving average price of $85.91 and a 200-day moving average price of $71.02.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. The business had revenue of $334.21 million for the quarter, compared to analyst estimates of $328.89 million. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The company’s revenue was up 84.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.46) earnings per share. Tempus AI has set its FY 2025 guidance at EPS. Equities research analysts predict that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.